A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
NCT06259552
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
232
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumor
HNSCC
RCC
CRC
Interventions
BIOLOGICAL:
SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
Sponsor
SparX Biotech(Jiangsu) Co., Ltd.